Causes of Elevated Hemoglobin with Negative JAK2 Marker
When JAK2 is negative in a patient with elevated hemoglobin, you must systematically evaluate for secondary causes of erythrocytosis, hereditary conditions, and rare JAK2-negative myeloproliferative disorders before labeling it as idiopathic erythrocytosis.
Primary Diagnostic Framework
The WHO diagnostic criteria acknowledge that while JAK2 mutations (V617F or exon 12) are present in approximately 95% of polycythemia vera cases, 5% of true PV cases may be JAK2-negative 1. However, JAK2-negative erythrocytosis more commonly represents secondary or hereditary causes 2, 3.
Immediate Assessment Steps
Measure serum erythropoietin (EPO) level - this single test provides critical diagnostic direction:
- Subnormal EPO: Suggests primary erythrocytosis (JAK2-negative PV or EPOR mutations)
- Normal/elevated EPO: Points toward secondary or hereditary causes 2, 3
Review historical hemoglobin/hematocrit values to distinguish:
- Longstanding/lifelong elevation → hereditary causes
- Recent/acquired elevation → secondary causes 2, 3
Major Causes by Category
1. Secondary Erythrocytosis (Acquired, Normal/High EPO)
Hypoxia-driven causes:
- Chronic lung disease (COPD, sleep apnea)
- Cyanotic heart disease
- High-altitude dwelling
- Chronic carbon monoxide exposure (smoking)
- Renal artery stenosis (peripheral hypoxia) 1, 2, 3
EPO-producing conditions:
- Renal cell carcinoma (most common tumor cause)
- Hepatocellular carcinoma
- Uterine leiomyomas
- Cerebellar hemangioblastoma 2, 3
Drug-induced:
- Testosterone/anabolic steroids
- SGLT2 inhibitors (increasingly recognized cause)
- Erythropoiesis-stimulating agents (ESAs) 2, 3
2. Hereditary Erythrocytosis (Longstanding, Variable EPO)
High oxygen-affinity hemoglobin variants (normal/high EPO):
- Over 100 variants described
- JAK2 V617F is definitively absent in these patients 4
- Requires hemoglobin electrophoresis and P50 measurement
Oxygen-sensing pathway mutations (high EPO):
- VHL (von Hippel-Lindau) - most common
- PHD2 (prolyl hydroxylase 2)
- HIF2A (hypoxia-inducible factor 2-alpha)
- Chuvash polycythemia (VHL mutation) - notable for thrombotic tendency 2, 3
EPOR mutations (subnormal EPO):
- Gain-of-function mutations in erythropoietin receptor
- Uniquely associated with LOW EPO despite erythrocytosis 2, 3
Other rare causes:
- 2,3-bisphosphoglycerate (2,3-BPG) deficiency
- PIEZO1 mutations
- Methemoglobinemia 3
3. JAK2-Negative Polycythemia Vera
If elevated hemoglobin meets WHO thresholds (Hgb >18.5 g/dL men, >16.5 g/dL women) with negative JAK2 testing, diagnosis requires 2 of 3 minor criteria 1:
- Bone marrow biopsy showing panmyelosis with trilineage proliferation
- Subnormal serum EPO
- Endogenous erythroid colony formation in vitro
Critical caveat: Bone marrow examination is mandatory when JAK2 is negative to establish PV diagnosis 5.
4. Apparent/Relative Polycythemia
- Volume contraction (dehydration, diuretics)
- Gaisbock syndrome (stress erythrocytosis)
- Physiological outliers at upper normal range 3
Diagnostic Algorithm
Step 1: Confirm true erythrocytosis (not volume contraction)
- Review serial hemoglobin/hematocrit measurements
- Consider red cell mass measurement if uncertain
Step 2: Measure serum EPO level
Step 3a - If EPO is LOW:
- Perform bone marrow biopsy to evaluate for JAK2-negative PV
- Test for EPOR mutations
- Consider endogenous erythroid colony assay
Step 3b - If EPO is NORMAL/HIGH:
- Assess for hypoxia: pulse oximetry, arterial blood gas, sleep study
- Evaluate for cardiopulmonary disease
- Screen for renal artery stenosis (imaging)
- Review medication list (testosterone, SGLT2-i)
- Abdominal imaging for EPO-producing tumors
Step 4 - If longstanding/family history:
- Hemoglobin P50 measurement (oxygen affinity)
- Genetic testing panel: VHL, PHD2, HIF2A, EPOR
- Consider expanded next-generation sequencing panel for hereditary erythrocytosis 3
Management Principles
Avoid cytoreductive therapy in secondary and hereditary erythrocytosis - this is fundamentally different from PV management 2, 3.
Phlebotomy should be symptom-driven, not hematocrit-threshold driven:
- No evidence supports aggressive phlebotomy targets
- Frequency determined by hyperviscosity symptoms (headache, dizziness, visual changes)
- Exception: Chuvash polycythemia has documented thrombotic risk 2
Cardiovascular risk optimization:
- Control hypertension, diabetes, hyperlipidemia
- Smoking cessation
- Low-dose aspirin (81 mg daily) often recommended, though evidence is limited 2, 3
Treat underlying cause when possible:
- CPAP for sleep apnea
- Revascularization for renal artery stenosis
- Tumor resection for EPO-producing neoplasms
- Discontinue causative medications
Common Pitfalls
- Assuming all erythrocytosis is PV: JAK2-negative cases are more likely secondary/hereditary than true PV
- Over-phlebotomizing: Can worsen symptoms and quality of life without proven benefit in non-PV erythrocytosis
- Missing drug causes: Always review SGLT2 inhibitors, testosterone, and ESAs 3
- Inadequate workup: Labeling as "idiopathic" without measuring EPO, checking family history, or considering hereditary causes
- Inappropriate cytoreduction: Using hydroxyurea or other agents in secondary erythrocytosis increases toxicity without benefit
If comprehensive workup is negative, consider expanded genetic testing with next-generation sequencing panels for hereditary erythrocytosis, as molecular advances continue to reclassify "idiopathic" cases 3.